Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 1034Neoplasms 815Carcinoma, Non-Small-Cell Lung 799Prostatic Neoplasms 621Colorectal Neoplasms 529Lung Neoplasms 486Neoplasm Metastasis 434Multiple Myeloma 395Leukemia, Myeloid, Acute 391Ovarian Neoplasms 334Pancreatic Neoplasms 316Melanoma 297Squamous Cell Carcinoma of Head and Neck 268Recurrence 256Carcinoma, Hepatocellular 250Glioblastoma 238Brain Neoplasms 237Triple Negative Breast Neoplasms 213Carcinoma, Renal Cell 209Head and Neck Neoplasms 208Precursor Cell Lymphoblastic Leukemia-Lymphoma 201Lymphoma 201Stomach Neoplasms 197Endometrial Neoplasms 189Uterine Cervical Neoplasms 185Lymphoma, Non-Hodgkin 180Glioma 180Sarcoma 179Lymphoma, Large B-Cell, Diffuse 167Hematologic Neoplasms 162

Interventions

1-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Platinum-resistant Ovarian Cancer × 90 days × Clear all
NCT05551507 2026-05-04

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡